Postoperative radiotherapy for advanced head and neck cancer in patients with cardiac pacemakers

2013 ◽  
Vol 13 (1) ◽  
pp. 115-118 ◽  
Author(s):  
Federico L. Ampil ◽  
Cherie-Ann Nathan ◽  
Ghali Ghali ◽  
David Kim
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Postoperative Radiotherapy ◽  
Locally Advanced ◽  
Clinical Situation ◽  
Cardiac Events ◽  
Cardiac Pacemakers ◽  
Postoperative Irradiation ◽  
Precautionary Measures

AbstractThe clinical situation of coexisting significant cardiac arrhythmias complicating head and neck cancer (HNC) is uncommon, accounting for <11% of comorbid illnesses present in this particular cohort of individuals. Little is documented about the outcomes of these people with cardiac pacemakers (CP) when surgery combined with postoperative radiotherapy is rendered. The authors report two cases wherein full-course postoperative irradiation was administered without any patient mishap. Appropriately indicated adjuvant radiotherapy for locally advanced HNC can be conducted safely and effectively in patients with CPs. Implementation of essential precautionary measures is encouraged to avoid any serious, unwanted cardiac events.

scholarly journals Postoperative Radiotherapy in Head and Neck Cancer

2010 ◽  
Vol 2 (1) ◽  
pp. 43-51
Author(s):  
Vedang Murthy ◽  
Sayan Kundu ◽  
Tanweer Shahid ◽  
Ashwini Budrukkar ◽  
Tejpal Gupta ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Targeted Therapy ◽  
Head And Neck ◽  
Neck Cancer ◽  
Early Stage ◽  
Postoperative Radiotherapy ◽  
Locally Advanced ◽  
Head And Neck Cancers ◽  
Advanced Head ◽  
Locoregional Failure

Abstract Though early stage head and neck cancers can be cured either by surgery or radiation, patients with locally advanced disease continues to pose a therapeutic challenge. Locoregional failure is the major cause of death in head and neck cancers. As the outcome of locally advanced head and neck cancer is less than promising, a combined modality approach is generally undertaken in this group of patients. The combination of surgery, radiation and more recently, chemotherapy and targeted therapy can improve outcomes in locally advanced head and neck cancer patients. This overview discusses the rationale and role of postoperative radiotherapy (PORT) in advanced head and neck cancers, the radiotherapy technique in brief and methods of enhancing the efficacy of postoperative RT by altering the fractionation schedules and adding chemotherapy and targeted therapy.

Postoperative Irradiation with or without Concomitant Chemotherapy for Locally Advanced Head and Neck Cancer

2004 ◽  
Vol 350 (19) ◽  
pp. 1945-1952 ◽  
Author(s):  
Jacques Bernier ◽  
Christian Domenge ◽  
Mahmut Ozsahin ◽  
Katarzyna Matuszewska ◽  
Jean-Louis Lefèbvre ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Locally Advanced ◽  
Advanced Head ◽  
Concomitant Chemotherapy ◽  
Postoperative Irradiation

Postoperative Radiotherapy in Locally Advanced Head and Neck Cancer

1989 ◽  
Vol 75 (1) ◽  
pp. 47-52 ◽  
Author(s):  
Giovanni Franchin ◽  
Antonino De Paoli ◽  
Carlo Gobitti ◽  
Giovanni Boz ◽  
Emilio Minatel ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Survival Rate ◽  
Head And Neck ◽  
Neck Cancer ◽  
Postoperative Radiotherapy ◽  
Locally Advanced ◽  
Disease Free Survival ◽  
Resection Margins ◽  
Combined Modality Treatment ◽  
Advanced Head

This retrospective study was conducted on 255 consecutive patients with locally advanced squamous-cell carcinoma of the oral cavity, oropharynx, larynx or hypopharynx, treated at the Radiotherapy Department of Pordenone General Hospital between January 1975 and December 1985. All patients underwent radical surgery followed, after an interval ranging from 10 days to 2.9 months, by radiotherapy given either through a 6 MeV linear accelerator or a cobalt-60 unit. Field extension and dose delivered were comparable in relation to stage and involvement of the surgical resection margins. The aims of the study were to evaluate the survival rate and to analyze the clinical parameters which can influence the disease-free survival. The adjusted overall 5-year survival rate was 71%; stage, performance status at diagnosis, and site of the primary tumor were significant factors in determining patient prognosis, whereas Infiltration of resection margins was not significant in determining locoregional control of disease. Seventy-five patients relapsed and 67 died of cancer-related diseases whereas death in 52 patients was not related to the head and neck cancer. The combined modality treatment consisting of surgery followed by radiotherapy was well tolerated and proved to be effective in the treatment of locally advanced head and neck tumors.

scholarly journals Postoperative radiotherapy with weekly cisplatin in locally advanced head and neck cancer

2017 ◽  
Vol 28 ◽  
pp. v383-v384
Author(s):  
A. Hervás ◽  
J. Domínguez ◽  
D. Candini ◽  
M. Martín ◽  
C. Vallejo
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Postoperative Radiotherapy ◽  
Locally Advanced ◽  
Advanced Head ◽  
Weekly Cisplatin

scholarly journals Postoperative chemoradiotherapy with cisplatin is superior to radioimmunotherapy with cetuximab and radiotherapy alone

2021 ◽  
Author(s):  
Teresa Magnes ◽  
Sandro M. Wagner ◽  
Thomas Melchardt ◽  
Lukas Weiss ◽  
Gabriel Rinnerthaler ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Cancer Registry ◽  
Neck Cancer ◽  
Postoperative Radiotherapy ◽  
Locally Advanced ◽  
Progression Free Survival ◽  
Patient Characteristics ◽  
High Dose ◽  
Radiotherapy Alone

Summary Background The addition of cisplatin or cetuximab to radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) has significantly improved the outcome. While the superiority of cisplatin over cetuximab in combination with radiotherapy has been shown in a definitive setting, we set out to compare postoperative chemoradiotherapy with cisplatin to radioimmunotherapy with cetuximab and radiotherapy alone within the Austrian head and neck cancer registry of the Working Group on Pharmaceutical Tumor Treatment (AGMT) study group. Material and methods In the AGMT head and neck cancer registry, data of 557 patients with SCCHN from five Austrian cancer centers were prospectively collected between 2012 and 2017. Of these patients 120 received postoperative chemoradiotherapy with cisplatin, 26 patients received postoperative radioimmunotherapy with cetuximab and 56 patients were treated with adjuvant radiotherapy only. Patient characteristics, stage of disease, details on treatment as well as survival were analyzed by a chart-based review. Results In patients treated with postoperative radiotherapy the addition of cisplatin significantly improved progression-free survival (PFS) and overall survival (OS) compared to cetuximab (PFS 84.2 months vs. 17.0 months, p = 0.04, OS not reached vs. 46.0 months, p = 0.02) and PFS compared to radiotherapy alone (PFS 84.2 months vs. 28.5 months, p < 0.01). Patients treated with cetuximab were significantly older and had a worse performance score than patients receiving cisplatin or radiotherapy alone. Conclusion This study confirmed the importance of multimodal treatment concepts in patients with locally advanced SCCHN. Postoperative cetuximab might be an option in patients not eligible for high-dose cisplatin but cisplatin should remain the standard of care.

scholarly journals Treatment outcome of postoperative radiotherapy for squamous cell carcinoma of the head and neck

2017 ◽  
Vol 4 (1) ◽  
pp. 127
Author(s):  
H. U. Ghori ◽  
M. Sohaib ◽  
Vivek Tiwari ◽  
Manish Ahirwar
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Early Stage ◽  
Postoperative Radiotherapy ◽  
Locally Advanced ◽  
Disease Status ◽  
Patient Characteristics ◽  
Neck Tumors ◽  
Modality Approach

<p class="abstract"><strong>Background:</strong> Though early stage malignancy of head and neck can be cured by surgery or radiotherapy, cure of patients with locally advanced disease continues to pose a therapeutic challenge. Loco regional failure is the major cause of death in head and neck cancer. As the cure of locally advance head and neck cancer is less than expectation, a combined modality approach is generally used in these type of patients. The combination of surgery, radiotherapy and chemotherapy can improve outcome in locally advance head and neck cancer.</p><p class="abstract"><strong>Methods:</strong> This observational study reviewed cancer patients reported in our hospital with the following inclusion criteria: primary head and neck cancer, treatment with radical surgery, and multiple nodal metastases. The prescribed dose of postoperative radiotherapy was 60–66 Gy. Patient characteristics, treatment parameters and clinical outcome were recorded.  </p><p class="abstract"><strong>Results:</strong> The primary end point was overall survival, and the secondary endpoint was disease status.</p><p><strong>Conclusions:</strong> Concurrent postoperative administration of chemotherapy and radiotherapy is a way to intensify treatment for resectable high-risk head and neck tumors.</p>

Sign in / Sign up

Export Citation Format

Share Document